Skip to content

Congratulations to BioLineRx on the Submission of their NDA to the FDA for Motixafortide in Stem Cell Mobilization


Congratulations to our clients at BioLineRX on the submission of their #NDA to the FDA for #Motixafortide in stem cell mobilization! As BioLineRx’s longtime #CRO partner, supporting their team with end-to-end #clinicaltrial data management, statistical programming and medical writing services, we’re proud to have been part of the pivotal GENESIS Phase 3 study, which met all primary and secondary endpoints with a very high degree of statistical significance. It’s an honor to collaborate with BioLineRx as they work to improve bone marrow transplantation treatments for multiple myeloma patients.

#clinicalresearch #datamanagement #stemcelltherapy #oncology #multiplemyeloma

Click here to learn more >>